RxDoctor Payments Data

Mary Mills, DO

Family Medicine · Broken Arrow, OKNPI 1316960339

Payments from drug & device makers

$667in general payments, 2019–2025

Across 44 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$209
  • Novo Nordisk$117
  • AbbVie$92
  • Astellas Pharma US Inc$53
  • Johnson & Johnson$42
  • Pfizer$41
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$64997%
  • Gifts$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK14$209
Novo Nordisk8$117
AbbVie5$92
Astellas Pharma US Inc4$53
Johnson & Johnson3$42
Pfizer3$41
Amgen(2 entities)2$35
Dexcom, Inc.2$27
Ascend Therapeutics US, LLC1$18
Bristol Myers Squibb1$17
Merck1$14

How this compares

$667 in reported general payments places this provider in the 55th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$93,907
Medicare patients
144
Services billed
5,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$96,753
TrulicityDulaglutide14$15,602
JanuviaSitagliptin Phosphate15$12,634
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,253
JardianceEmpagliflozin13$8,162
PremarinEstrogens, Conjugated19$5,825
SynthroidLevothyroxine Sodium50$5,696
Rosuvastatin Calcium289$4,705
Atorvastatin Calcium252$2,766
Celecoxib78$2,365
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$1,891
Omeprazole86$1,868
Losartan Potassium133$1,675
Ezetimibe65$1,651
Fenofibrate80$1,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$96,75394 claims
MerckJanuvia$14$12,63415 claims
PfizerPremarin$41$5,82519 claims
AbbVieSynthroid$92$5,69650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →